Gui-hui Wu

The safety and efficacy of different anti-tuberculosis regimens containing Lzd for RR/MDR/Pre-XDR-TB patients in China

China remains a high-burden country for rifampicin-resistant tuberculosis. The treatment of drug-resistant tuberculosis is expensive, with many adverse drug reactions and greater difficulty to cure. Searching for appropriate treatment regimens is urgent. A retrospective study was...